Sponsor Pipeline

Zydus Therapeutics Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
4
Recruiting
3
Phase 3
1
Disease Areas
8
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-29 NCT07023835
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral…		 Enrollment reopened
2026-07-29 NCT07216235
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary…		 Recruitment opened
2026-07-29 NCT07216235
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary…		 Trial sites expanded: 0 -> 3 locations
2026-07-29 NCT05045482
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease		 Primary endpoint(s) modified
2026-07-29 NCT05045482
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease		 date change Primary completion pushed: 2026-03-31 -> 2026-07-31
2026-07-29 NCT05045482
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease		 date change Completion pushed: 2026-03-31 -> 2026-07-31
2026-07-29 NCT06825559
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to…		 date change Primary completion pushed: 2025-12-31 -> 2026-07-31
2026-07-29 NCT06825559
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to…		 date change Completion pushed: 2025-12-31 -> 2026-07-31
Active Trials by Phase
Phase 3
3
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07216235 Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary… Primary Biliary Cholangitis Recruiting
NCT06427395 Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary… Primary Biliary Cholangitis Active, Not Recruiting
NCT07424677 Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant… Primary Biliary Cholangitis Not Yet Recruiting
Phase 2
NCT07023835 Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral… Amyotrophic Lateral Sclerosis (ALS) Recruiting
Phase 1
NCT05045482 Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease Hepatic Impairment Recruiting
NCT06825559 Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to… Cholestatic Liver Disease Recruiting
Disease Areas
ALS (1)
Get alerts when Zydus Therapeutics Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free